Allergy Thera. Share News (AGY)

AIM WINNERS & LOSERS: Allergy Therapeutics plunges as results delayed

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

LONDON MARKET OPEN: Sea of red as investors fret over Covid in China

(Alliance News) - Stock prices in London opened lower on Thursday amid risk-off sentiment across Europe, as concerns grew about rising Covid cases in China.

Allergy Therapeutics shares halve as delayed audit to mean suspension

Alliance News) - Allergy Therapeutics PLC on Thursday said it shares will be suspended next week, due to delays in completing the audit of its annual results.

AIM WINNERS & LOSERS: Redcentric boasts "transformational" half-year

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Allergy Therapeutics proffers peanut progress despite cost concerns

(Alliance News) - Allergy Therapeutics PLC on Thursday saw shares drop despite the start of its peanut allergy testing trial, after it confirmed that cost control remains a preoccupation for management following a pause in production earlier in the year.

Allergy Therapeutics hires interim CFO as Nick Wykeman steps down

(Alliance News) - Allergy Therapeutics PLC on Monday said it appointed Martin Hopcroft as interim chief financial officer, as Nick Wykeman will step down at the end of November.

AIM WINNERS & LOSERS: Directa Plus wins deal; Greatland loss widens

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

IN BRIEF: Allergy Therapeutics resumes output; warns on revenue miss

Allergy Therapeutics PLC - West Sussex-based commercial biotechnology company - Says it will resume production at Freeman facility in Worthing, UK on November 14. This follows a short-term voluntary pause as it reviewed its operating processes. Says the pause was planned, to help improve "robustness" of quality systems and build capacity. It was then accelerated when the firm realised capacity could not cope with commercial demand. "The pause in manufacturing occurred during a period of peak production prior to the start of the pollen season in the spring," it says. Consequently, it estimates revenue will be around 13% to 18% lower than market expectations of around GBP80 million, for the year to June 30.

TRADING UPDATES: IQE, Trellus Health and Insig sign new agreements

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Allergy Therapeutics pauses production at Freeman facility

(Sharecast News) - Biotechnology company Allergy Therapeutics has "proactively paused" production at the Freeman facility, part of its Worthing manufacturing site, to accelerate ongoing site improvements, it announced on Tuesday.

AIM WINNERS & LOSERS: N4's Nuvec success; Watkin Jones tumbles

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Allergy Therapeutics shares down as pauses production at UK facility

(Alliance News) - Allergy Therapeutics PLC shares dropped on Tuesday following production at the Freeman facility, part of its Worthing, UK manufacturing site, being paused.

Allergy Therapeutics shares down as pauses production at UK facility

(Alliance News) - Allergy Therapeutics PLC shares dropped on Tuesday following production at the Freeman facility, part of its Worthing, UK manufacturing site, being paused.

TRADING UPDATES: H&T plans raise; Joules turnaround continues

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days